| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 87 | 2023 | 5319 | 8.740 |
Why?
|
| Lung Neoplasms | 127 | 2024 | 11538 | 7.960 |
Why?
|
| Pneumonectomy | 35 | 2023 | 831 | 4.150 |
Why?
|
| Mesothelioma | 12 | 2022 | 544 | 2.260 |
Why?
|
| Esophagectomy | 18 | 2022 | 911 | 2.100 |
Why?
|
| Esophageal Neoplasms | 23 | 2023 | 3168 | 2.030 |
Why?
|
| Pleural Neoplasms | 7 | 2022 | 470 | 1.910 |
Why?
|
| Neoadjuvant Therapy | 32 | 2023 | 4975 | 1.880 |
Why?
|
| Thoracic Surgical Procedures | 8 | 2022 | 261 | 1.710 |
Why?
|
| Thoracic Wall | 3 | 2018 | 183 | 1.550 |
Why?
|
| Adenocarcinoma | 24 | 2023 | 7789 | 1.430 |
Why?
|
| Neoplasm Staging | 48 | 2023 | 13658 | 1.330 |
Why?
|
| Retrospective Studies | 77 | 2023 | 37905 | 1.100 |
Why?
|
| B7-H1 Antigen | 9 | 2023 | 1022 | 1.070 |
Why?
|
| Humans | 177 | 2024 | 261506 | 1.030 |
Why?
|
| Thoracic Neoplasms | 2 | 2018 | 337 | 0.970 |
Why?
|
| Lymph Nodes | 8 | 2021 | 2967 | 0.960 |
Why?
|
| Aged | 85 | 2022 | 70117 | 0.910 |
Why?
|
| Ipilimumab | 4 | 2023 | 710 | 0.910 |
Why?
|
| Middle Aged | 87 | 2022 | 86204 | 0.880 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2023 | 10035 | 0.870 |
Why?
|
| Radiosurgery | 6 | 2021 | 1330 | 0.810 |
Why?
|
| Postoperative Complications | 17 | 2022 | 5542 | 0.800 |
Why?
|
| Immunotherapy | 13 | 2023 | 3341 | 0.780 |
Why?
|
| Databases, Factual | 17 | 2020 | 2218 | 0.770 |
Why?
|
| Small Cell Lung Carcinoma | 6 | 2023 | 406 | 0.760 |
Why?
|
| Metastasectomy | 5 | 2023 | 200 | 0.750 |
Why?
|
| Pleura | 1 | 2021 | 127 | 0.730 |
Why?
|
| Male | 93 | 2022 | 123000 | 0.730 |
Why?
|
| Perioperative Care | 4 | 2020 | 451 | 0.720 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2021 | 5437 | 0.710 |
Why?
|
| Female | 95 | 2022 | 141928 | 0.710 |
Why?
|
| Multivariate Analysis | 10 | 2019 | 4298 | 0.700 |
Why?
|
| Aged, 80 and over | 43 | 2022 | 29902 | 0.680 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 8 | 2022 | 992 | 0.640 |
Why?
|
| Treatment Outcome | 39 | 2023 | 32848 | 0.640 |
Why?
|
| Thoracic Surgery, Video-Assisted | 6 | 2022 | 209 | 0.640 |
Why?
|
| Chemoradiotherapy, Adjuvant | 5 | 2021 | 565 | 0.630 |
Why?
|
| Proportional Hazards Models | 10 | 2022 | 4988 | 0.620 |
Why?
|
| Follow-Up Studies | 23 | 2021 | 14889 | 0.620 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2019 | 6207 | 0.610 |
Why?
|
| Time Factors | 19 | 2022 | 12926 | 0.600 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 406 | 0.600 |
Why?
|
| Survival Rate | 20 | 2024 | 12221 | 0.590 |
Why?
|
| Thoracoplasty | 1 | 2016 | 20 | 0.570 |
Why?
|
| Survival Analysis | 16 | 2021 | 9180 | 0.570 |
Why?
|
| Sternoclavicular Joint | 1 | 2016 | 7 | 0.560 |
Why?
|
| Lung Diseases | 3 | 2021 | 717 | 0.560 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 450 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 8873 | 0.540 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1249 | 0.540 |
Why?
|
| Thoracotomy | 4 | 2022 | 220 | 0.540 |
Why?
|
| Disease-Free Survival | 15 | 2021 | 10001 | 0.530 |
Why?
|
| Esophagoscopy | 4 | 2021 | 291 | 0.530 |
Why?
|
| Neutrophils | 1 | 2020 | 835 | 0.530 |
Why?
|
| Pain, Postoperative | 4 | 2021 | 610 | 0.530 |
Why?
|
| Biomarkers, Tumor | 13 | 2023 | 10331 | 0.520 |
Why?
|
| Prognosis | 27 | 2024 | 21713 | 0.500 |
Why?
|
| Surgical Mesh | 1 | 2016 | 209 | 0.500 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1048 | 0.490 |
Why?
|
| Molecular Targeted Therapy | 4 | 2022 | 2330 | 0.490 |
Why?
|
| Lung | 13 | 2023 | 3151 | 0.480 |
Why?
|
| Neoplasm Invasiveness | 8 | 2019 | 3981 | 0.480 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2022 | 3890 | 0.480 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2021 | 1763 | 0.470 |
Why?
|
| Adult | 43 | 2022 | 77950 | 0.470 |
Why?
|
| Texas | 11 | 2019 | 6311 | 0.460 |
Why?
|
| Propensity Score | 5 | 2021 | 750 | 0.450 |
Why?
|
| Osteomyelitis | 1 | 2016 | 236 | 0.450 |
Why?
|
| Stomach | 3 | 2012 | 387 | 0.440 |
Why?
|
| Body Mass Index | 2 | 2017 | 2203 | 0.440 |
Why?
|
| Tumor Microenvironment | 11 | 2022 | 2864 | 0.430 |
Why?
|
| Cancer Care Facilities | 7 | 2019 | 884 | 0.420 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 71 | 0.420 |
Why?
|
| Logistic Models | 10 | 2019 | 3441 | 0.410 |
Why?
|
| Omentum | 1 | 2012 | 96 | 0.410 |
Why?
|
| Analgesics, Opioid | 5 | 2021 | 1371 | 0.410 |
Why?
|
| Colorectal Neoplasms | 7 | 2023 | 3578 | 0.410 |
Why?
|
| Cohort Studies | 12 | 2021 | 9244 | 0.400 |
Why?
|
| Salvage Therapy | 7 | 2021 | 2054 | 0.400 |
Why?
|
| Pain Management | 3 | 2021 | 668 | 0.400 |
Why?
|
| Sutures | 1 | 2011 | 86 | 0.400 |
Why?
|
| Melanoma | 3 | 2023 | 5317 | 0.390 |
Why?
|
| Pancreatic Fistula | 1 | 2011 | 99 | 0.390 |
Why?
|
| Breast Implants | 1 | 2016 | 391 | 0.380 |
Why?
|
| Esophageal Perforation | 1 | 2010 | 25 | 0.370 |
Why?
|
| 5'-Nucleotidase | 2 | 2021 | 61 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2024 | 7551 | 0.370 |
Why?
|
| Young Adult | 15 | 2020 | 21445 | 0.360 |
Why?
|
| Lymphatic Metastasis | 7 | 2021 | 4844 | 0.360 |
Why?
|
| Chemoradiotherapy | 6 | 2021 | 1946 | 0.360 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2024 | 1226 | 0.350 |
Why?
|
| Risk Assessment | 13 | 2022 | 6869 | 0.340 |
Why?
|
| Positron-Emission Tomography | 4 | 2021 | 2173 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 15862 | 0.340 |
Why?
|
| Consolidation Chemotherapy | 2 | 2019 | 155 | 0.330 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 709 | 0.320 |
Why?
|
| Patient Discharge | 4 | 2021 | 661 | 0.320 |
Why?
|
| Circulating Tumor DNA | 2 | 2023 | 235 | 0.310 |
Why?
|
| Thoracic Surgery | 2 | 2023 | 295 | 0.310 |
Why?
|
| Sarcoma | 1 | 2018 | 1725 | 0.310 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2019 | 94 | 0.310 |
Why?
|
| Risk Factors | 16 | 2023 | 17523 | 0.300 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1021 | 0.300 |
Why?
|
| Immunologic Factors | 2 | 2021 | 649 | 0.300 |
Why?
|
| Patient Selection | 5 | 2021 | 2055 | 0.300 |
Why?
|
| Pancreatectomy | 1 | 2011 | 652 | 0.300 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 1586 | 0.290 |
Why?
|
| Registries | 4 | 2018 | 2170 | 0.290 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 8865 | 0.280 |
Why?
|
| Esophagogastric Junction | 3 | 2023 | 543 | 0.280 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 394 | 0.280 |
Why?
|
| Precancerous Conditions | 3 | 2024 | 1058 | 0.280 |
Why?
|
| Prospective Studies | 9 | 2021 | 12873 | 0.270 |
Why?
|
| Surgical Flaps | 1 | 2012 | 927 | 0.270 |
Why?
|
| Robotic Surgical Procedures | 3 | 2021 | 481 | 0.260 |
Why?
|
| Transcriptome | 3 | 2021 | 1859 | 0.240 |
Why?
|
| Mutation | 11 | 2024 | 15179 | 0.240 |
Why?
|
| Thymus Neoplasms | 2 | 2020 | 400 | 0.240 |
Why?
|
| CD3 Complex | 2 | 2022 | 314 | 0.230 |
Why?
|
| Incidence | 7 | 2021 | 5673 | 0.230 |
Why?
|
| United States | 15 | 2023 | 15433 | 0.230 |
Why?
|
| Cytokines | 4 | 2020 | 2809 | 0.230 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2024 | 833 | 0.220 |
Why?
|
| Adolescent | 12 | 2021 | 31252 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2020 | 2231 | 0.220 |
Why?
|
| Odds Ratio | 5 | 2021 | 2316 | 0.220 |
Why?
|
| Paranasal Sinuses | 1 | 2022 | 61 | 0.210 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 85 | 0.210 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1323 | 0.210 |
Why?
|
| Tumor Burden | 4 | 2023 | 1987 | 0.210 |
Why?
|
| Judgment | 1 | 2021 | 47 | 0.200 |
Why?
|
| Sex Factors | 4 | 2020 | 2139 | 0.200 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2022 | 69 | 0.200 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 24 | 0.200 |
Why?
|
| Chest Tubes | 1 | 2021 | 101 | 0.200 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 31 | 0.200 |
Why?
|
| Analysis of Variance | 3 | 2018 | 2307 | 0.190 |
Why?
|
| SEER Program | 3 | 2019 | 1000 | 0.190 |
Why?
|
| Patient Readmission | 3 | 2021 | 548 | 0.190 |
Why?
|
| Bupivacaine | 1 | 2020 | 68 | 0.180 |
Why?
|
| Utopias | 1 | 2019 | 1 | 0.180 |
Why?
|
| Hernia, Hiatal | 2 | 2009 | 63 | 0.180 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 1062 | 0.180 |
Why?
|
| Elective Surgical Procedures | 2 | 2012 | 250 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2022 | 716 | 0.170 |
Why?
|
| Epithelial Cells | 2 | 2024 | 1818 | 0.170 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 170 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 162 | 0.170 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 672 | 0.170 |
Why?
|
| Microwaves | 1 | 2018 | 32 | 0.170 |
Why?
|
| Stomach Neoplasms | 2 | 2023 | 2278 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 6009 | 0.160 |
Why?
|
| Interleukin-2 | 1 | 2022 | 842 | 0.160 |
Why?
|
| Immunogenetics | 1 | 2018 | 16 | 0.160 |
Why?
|
| Treatment Refusal | 1 | 2019 | 128 | 0.160 |
Why?
|
| Linear Models | 2 | 2018 | 1085 | 0.160 |
Why?
|
| Carcinogenesis | 2 | 2021 | 1026 | 0.160 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 280 | 0.150 |
Why?
|
| Nomograms | 1 | 2020 | 313 | 0.150 |
Why?
|
| Natural Language Processing | 1 | 2018 | 119 | 0.150 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 669 | 0.150 |
Why?
|
| Travel | 1 | 2019 | 190 | 0.150 |
Why?
|
| Disease Progression | 4 | 2021 | 6682 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 360 | 0.150 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 550 | 0.150 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 3869 | 0.150 |
Why?
|
| Serine Proteases | 1 | 2017 | 20 | 0.150 |
Why?
|
| Ticlopidine | 1 | 2017 | 95 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 4892 | 0.140 |
Why?
|
| Dasatinib | 1 | 2020 | 862 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 113 | 0.140 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 5112 | 0.140 |
Why?
|
| Preoperative Care | 2 | 2019 | 1529 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 634 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2017 | 388 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 821 | 0.140 |
Why?
|
| Antigen Presentation | 1 | 2017 | 272 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1331 | 0.140 |
Why?
|
| Reoperation | 3 | 2019 | 1382 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 2018 | 256 | 0.140 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 137 | 0.140 |
Why?
|
| Reference Values | 1 | 2018 | 1099 | 0.140 |
Why?
|
| Diaphragm | 1 | 2017 | 181 | 0.130 |
Why?
|
| Genomics | 3 | 2021 | 2738 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 551 | 0.130 |
Why?
|
| Perioperative Period | 1 | 2016 | 155 | 0.130 |
Why?
|
| Acellular Dermis | 1 | 2017 | 103 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2021 | 712 | 0.130 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 32 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2017 | 242 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2022 | 5159 | 0.130 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 14289 | 0.130 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 569 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2019 | 712 | 0.130 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 475 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 1146 | 0.130 |
Why?
|
| Macrophages | 2 | 2019 | 1304 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 1648 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2020 | 211 | 0.120 |
Why?
|
| Cisplatin | 2 | 2020 | 2432 | 0.120 |
Why?
|
| Taxoids | 1 | 2017 | 967 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2021 | 2669 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2019 | 787 | 0.120 |
Why?
|
| Thymoma | 1 | 2017 | 246 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 444 | 0.120 |
Why?
|
| Genetic Heterogeneity | 3 | 2021 | 318 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 225 | 0.120 |
Why?
|
| Confidence Intervals | 2 | 2018 | 756 | 0.120 |
Why?
|
| Length of Stay | 2 | 2018 | 1900 | 0.110 |
Why?
|
| Hoarseness | 1 | 2012 | 25 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 7548 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2024 | 4078 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 761 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 739 | 0.110 |
Why?
|
| Cause of Death | 1 | 2015 | 752 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 15694 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 904 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3230 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 461 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1274 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1910 | 0.100 |
Why?
|
| Consensus | 3 | 2023 | 978 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 7222 | 0.100 |
Why?
|
| Cough | 1 | 2012 | 116 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1866 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 755 | 0.100 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 1959 | 0.100 |
Why?
|
| Emergencies | 2 | 2009 | 202 | 0.100 |
Why?
|
| Radiopharmaceuticals | 3 | 2021 | 1301 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1258 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2011 | 108 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2016 | 1450 | 0.100 |
Why?
|
| Anastomosis, Surgical | 1 | 2012 | 371 | 0.100 |
Why?
|
| Child | 5 | 2018 | 29154 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 5687 | 0.090 |
Why?
|
| Age Factors | 1 | 2020 | 5377 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 915 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1819 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1506 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 498 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 1823 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 334 | 0.090 |
Why?
|
| GPI-Linked Proteins | 2 | 2021 | 223 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 1904 | 0.090 |
Why?
|
| Clone Cells | 2 | 2021 | 555 | 0.090 |
Why?
|
| Mucous Membrane | 1 | 2010 | 271 | 0.090 |
Why?
|
| Vascular Neoplasms | 1 | 2010 | 114 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2018 | 6150 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2019 | 1797 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2291 | 0.080 |
Why?
|
| Telephone | 2 | 2021 | 163 | 0.080 |
Why?
|
| Patient Admission | 1 | 2009 | 220 | 0.080 |
Why?
|
| Oxygen | 1 | 2012 | 754 | 0.080 |
Why?
|
| Gastrectomy | 2 | 2023 | 451 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4367 | 0.080 |
Why?
|
| Prevalence | 3 | 2010 | 3260 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 2104 | 0.080 |
Why?
|
| Mediastinum | 2 | 2019 | 268 | 0.080 |
Why?
|
| ErbB Receptors | 3 | 2020 | 2295 | 0.080 |
Why?
|
| Cell Survival | 1 | 2013 | 3045 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2023 | 1016 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 627 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2017 | 235 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 4549 | 0.070 |
Why?
|
| Neoplasms | 2 | 2023 | 15193 | 0.070 |
Why?
|
| Postoperative Care | 2 | 2021 | 739 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 4849 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 2315 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2019 | 1391 | 0.060 |
Why?
|
| Heterografts | 2 | 2019 | 733 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2021 | 1681 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 1516 | 0.060 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2024 | 46 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 1294 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 14551 | 0.060 |
Why?
|
| Stents | 1 | 2010 | 1096 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2021 | 11965 | 0.060 |
Why?
|
| Software | 2 | 2022 | 1321 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 1688 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2019 | 1869 | 0.060 |
Why?
|
| Infant | 1 | 2018 | 13310 | 0.060 |
Why?
|
| Carcinogens | 1 | 2024 | 384 | 0.050 |
Why?
|
| Tobacco Products | 1 | 2024 | 120 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2024 | 369 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 3472 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2011 | 1225 | 0.050 |
Why?
|
| Income | 1 | 2023 | 222 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2002 | 97 | 0.050 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 16273 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 103 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 1656 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2022 | 192 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 65 | 0.050 |
Why?
|
| Ecosystem | 1 | 2022 | 111 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 94 | 0.050 |
Why?
|
| Organoids | 1 | 2024 | 287 | 0.050 |
Why?
|
| Animals | 7 | 2024 | 59536 | 0.050 |
Why?
|
| Intercostal Nerves | 1 | 2020 | 33 | 0.050 |
Why?
|
| Smoking | 2 | 2021 | 2440 | 0.050 |
Why?
|
| New York | 2 | 2010 | 104 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 212 | 0.050 |
Why?
|
| Neck | 1 | 2022 | 383 | 0.050 |
Why?
|
| Thymectomy | 1 | 2020 | 79 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2021 | 223 | 0.050 |
Why?
|
| Aftercare | 1 | 2021 | 259 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 233 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2022 | 486 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2020 | 162 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2022 | 1053 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 429 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 485 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 163 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 756 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2021 | 557 | 0.040 |
Why?
|
| Metaplasia | 1 | 2021 | 383 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 483 | 0.040 |
Why?
|
| Drainage | 1 | 2021 | 416 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2021 | 251 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 289 | 0.040 |
Why?
|
| Antioxidants | 1 | 2002 | 507 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 206 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 315 | 0.040 |
Why?
|
| Nerve Block | 1 | 2020 | 176 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 764 | 0.040 |
Why?
|
| Adenosine | 1 | 2020 | 289 | 0.040 |
Why?
|
| Cerebellum | 1 | 2002 | 449 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 482 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.040 |
Why?
|
| Mice | 4 | 2024 | 34495 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 217 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 374 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 486 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2020 | 253 | 0.040 |
Why?
|
| Thoracoscopy | 1 | 2019 | 101 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 472 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 269 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 524 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2002 | 558 | 0.040 |
Why?
|
| North America | 1 | 2018 | 314 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 6942 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 470 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 126 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 598 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 629 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 905 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 182 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 673 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 677 | 0.040 |
Why?
|
| CD57 Antigens | 1 | 2016 | 20 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2020 | 953 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2017 | 159 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 134 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 834 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 980 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1026 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1248 | 0.030 |
Why?
|
| Recurrence | 1 | 2023 | 4758 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 1742 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Machine Learning | 1 | 2017 | 319 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 1664 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1163 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 860 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 462 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1014 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1271 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 703 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 2283 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 1960 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 582 | 0.030 |
Why?
|
| Aging | 1 | 2002 | 1582 | 0.030 |
Why?
|
| Esophageal pH Monitoring | 1 | 2012 | 9 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 1863 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1303 | 0.030 |
Why?
|
| Manometry | 1 | 2012 | 74 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2018 | 1234 | 0.030 |
Why?
|
| Fundoplication | 1 | 2012 | 56 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 3443 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2352 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2020 | 1154 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 1335 | 0.030 |
Why?
|
| Genome, Human | 1 | 2020 | 1869 | 0.030 |
Why?
|
| Oximetry | 1 | 2012 | 172 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 1385 | 0.020 |
Why?
|
| Remission Induction | 1 | 2017 | 3569 | 0.020 |
Why?
|
| Peptides | 1 | 2017 | 1479 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 4233 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 3639 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6295 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5710 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2010 | 344 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 4938 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4744 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 3842 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3890 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5178 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7226 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2010 | 899 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7702 | 0.010 |
Why?
|
| Cucumis sativus | 1 | 2002 | 1 | 0.010 |
Why?
|
| Spirulina | 1 | 2002 | 3 | 0.010 |
Why?
|
| Iontophoresis | 1 | 2002 | 15 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6100 | 0.010 |
Why?
|
| Malus | 1 | 2002 | 9 | 0.010 |
Why?
|
| Malondialdehyde | 1 | 2002 | 47 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2002 | 224 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2002 | 333 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2002 | 110 | 0.010 |
Why?
|
| Neural Inhibition | 1 | 2002 | 147 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2002 | 272 | 0.010 |
Why?
|
| Purkinje Cells | 1 | 2002 | 143 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2002 | 269 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 664 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2002 | 1029 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 6086 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 2522 | 0.010 |
Why?
|